and LHRH Analog Treatment in
|
|
- Cameron Wilkerson
- 5 years ago
- Views:
Transcription
1 Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National Children's Hospital, and **Department of Endocrinology & Metabolism, National Children's Medical Research Center, Tokyo 154, Japan Abstract. It has been reported that the final height in short children is strongly related to the height at the onset of pubertal development, and pubertal heiht gain in GH-treated children is not exceed the gain in normal children. Therefore, it is now the consensus that insufficient height at the onset of puberty leads to short final height. We have already demonstrated that the final height in GH-deficient children with spontaneous puberty with gonadal suppression therapy by medroxyprogesterone or cyproterone acetate was significantly taller than GHD with spontaneous puberty without gonadal suppression therapy. In this study, we treated short boys who started puberty at height shorter than 130 cm with combined GH and LHRH analog. Final height was predicted by the height SD score for bone age. Although pubertal growth spurt was not recognized in short children on combination treatment, bone age maturation over 11.5 years decelerated significantly to the rate of one year in three or four years. Even during this slow bone maturation period, growth velocity remained at 4 cm/year due to GH treatment. Therefore, height SDS for bone age was improved in combination with the elongation of treatment period by the slow bone maturation. Some investigators recommend not to delay induction if puberty much beyond the normal age to avoid psychological problems and ennuchoid proportion in these children. When we explained to our Japanese patients the chance of increasing the final height with gonadal suppression treatment and the risk of delaying the pubertal development, almost all children preferred taller final height to pubertal development and they did not experience much psychological trouble. The differences in social and cultural circumstances do, however, influence patients' preferences. Key words: GHD, Non-endocrine s hort stature, Puberty, Gonadal suppression treatment, GH treatment (Endocrine Journal 43 (Suppl): ,1996) Final Height in Isolated GHD Though GH treatment has been employed in Japan for more than 20 years since 1975, the final height of GH treated patients is still unsatisfactory: the mean final height standard deviation (SD) score in GH-treated patients without gonadotropin deficiency does not exceed -2 SD [1]. The main reason why GH-treated patients without go- Correspondence to: Dr. Toshiaki TANAKA, Division of Endocrinology & Metabolism, National Children's Hospital, Taishido, Setagaya-ku, Tokyo 154, Japan nadotropin deficiency have not achieved normal height is their relatively early pubertal onset when still short and rather smaller pubertal height gain than in normal children [2]. Height at the onset of puberty is closely related to final height in children with GHD [3], non-ghd short children [4] and normal children [5]. Figure 1 shows the natural linear growth in twelve non-ghd short boys at 7 years, onset of pubertal growth spurt, and 18 years. Only two short boys' height SD score exceed -2 SD [6]. Age at the onset of pubertal growth spurt is not so early, but height is shorter than in normal children. Since pubertal height gain is no greater in these short children than in normal children, they end
2 S14 TANAKA et al. Fig. 2. Mean prepubertal and deficient boys [7]. pubertal growth in GH Fig. 1. Height at 7 years, at the onset of pubertal growth spurt and at 18 years in short boys who were followed up without any treatment [6]. up shorter than normal as adults. Most of these children are classifiable as intrauterine growth retardation (IUGR) or familial short stature (FSS). Short height at the onset of puberty is therefore the main reason for short adult height in non-ghd short stature: once short children enter puberty, they will be short as adults. Fig. 3. Mean prepubertal and pubertal growth in GH deficient girls [7]. Gonadal Suppression Treatment in Combination with GH Treatment We have already reported that combined gonadal suppression therapy and GH treatment could increase final height in GHD patients [7]. As shown in Figs. 2 and 3, final height was significantly shorter in patients with spontaneous puberty without gonadal suppression treatment (GST) than in patients with combined gonadotropin deficiency, whose pubertal development was induced at an older age. The presence of normal gonadal function did therefore not help to achieve normal adult height with GH treatment. This advantage in GHD with spontaneous puberty could be overcome partially by combined GST. The mean duration of GST was 4.4 years. GST significantly increased the duration of puberty and total pubertal height gain. The gonadal suppressive agents used in previous studies were medroxyprogesterone or cyproterone acetate. Their gonadal suppressive effect was insufficient, however, and side effects such as obesity and general malaise have been reported. Since LHRH analog has a strong gonadal suppressive effect without serious side effects, we have treated boys who enter puberty short with the combined LHRH analog and GH to increase their final height. The LHRH analog used for the combination treatment was leuprolide acetate in microcapsule form (30-90,ug/kg, subcutaneous injection every four weeks) or tryptorelin in microcapsule form (60 ug/
3 COMBINED GH AND LHRH ANALOG TREATMENT IN SHORT CHILDREN S15 kg, intramuscular injection every four weeks); the GH was Genotropin ( U/kg/week, daily subcutaneous injection). Bone age was estimated by the Tanner-Whitehouse (TW) 2 RUS method standardized for Japanese children [8]. Predicted adult height was estimated by the Bayley-Pinneau method standardized for Japanese children [9] and by the projected height SD score for bone age. Figure 4 shows data from a typical patient with familial short stature. His testicular enlargement began at 10.5 years, when his height was at 123 cm and bone age was 10.5 years; at the time when his adult height was predicted to be cm by the projected height SDS for bone age method and cm by the Bayley-Pinneau method. His treatment was started with 60, tg/kg of tryptorelin at years and 0.5 U/kg/week of GH at 11 years. Growth velocity was 6.7 cm/year in the first year and 5.2 cm/year in the second year. GH was increased to 1.0 U/kg/week and the increased GH dose effectively maintained growth velocity: his growth velocity remained at 6.0 cm/year in the third year, 6.4 cm/year in the fourth year and 5.4 cm/year in the fifth year. He has been treated with the combination treatment for 5.83 years. His bone age has advanced only 2.9 years and his height more than 30 cm during this treatment period. Although his pubertal stage remained at 6 ml of testicular volume, the penis at Tanner stage 3, and pubic hair at Tanner stage 2, he has not complained about pubertal delay and is still eager to become taller. He discontinued LHRH analog at years at cm, when his predicted adult height was cm by the projected height SDS for bone age method and cm by the Bayley- Pinneau method. Predicted height increased by 15.4 cm and 18.6 cm, respectively. Only one patient with familial short stature has reached a nearly final height of cm (Fig. 5). His testicular enlargement began at 12 years when his height was 130 cm and bone age was 11 years; at that time, when his adult height was predicted to be cm by the projected height SDS for the bone age method and cm by the Bayley-Pinneau method. Combination treatment with 60 jig/ kg of tryptorelin and 0.5 U/kg/week of GH was started one year after his onset of puberty at cm with a bone age of 12 years. He had been treated for 2.8 years when he stopped LHRH analog at cm. He gained 17 cm and his bone age advanced only 0.8 years during this combination treatment. At the cessation of LHRH analog, his adult height was estimated to be cm by the projected height SDS for the bone age method and cm by the Bayley-Pinneau method. His pubertal stage was Tanner 3 at the start of treatment and remained at almost the same level during the combination treatment. He gained almost 10 cm while taking GH after the cessation of LHRH analog and his puberty developed to Tanner stage 5 in two years. He is satisfied with his height. Twenty-one boys who entered puberty shorter than 130 cm were enrolled in the combination treatment with informed consent. Their mean predicted adult height was estimated to be cm by projected height SDS for the bone age method and cm by the Bayley-Pinneau method. Seven patients discontinued LHRH analog treatment when their mean age was years and their mean height was cm after a mean treatment period of 4.96 years, when their predicted adult height was cm and cm, respectively. The remaining fourteen are receiving the combi-
4 S16 TANAKA et al. Fig. 5. A growth chart of a boy who has received and stopped combination treatment and reached a nearly final height. nation treatment after a mean period of 3.75 years. All except one patient are continuing GH treatment alone after cessation of LHRH analog and will continue it until they reach their final height. Combined LHRH analog and GH treatment can increase the adult height of short children who entered puberty early for height, but although there were no serious adverse events of these patients during the treatment, there are some problems in this combination treatment. The main problem is perhaps the psychosocial problems caused by delayed puberty, since this combined treatment must continue for at least three years. Before the treatment, we explain to both patient and parents the chances of increasing final height with the combination treatment and the risks of delaying pubertal development. We treat only those patients who strongly wish for a taller adult height. There may be cultural differences among countries: in Japan most patients prefer taller final height to normal pubertal development. Another problem may be decreased bone mineral density caused by suppressed sex steroids. This is now being studied. A couple of points can be improved. The first is the timing of the start of the combination treatment. Since bone age is not decelerated before 11.5 years anyway, we can wait to start the treatment until the bone age exceeds 11.5 years. This delayed start may induce further pubertal development as well as a stronger pubertal growth spurt and may shorten the treatment period. The second is the timing of the cessation of LHRH analog treatment. We could stop the combination treatment earlier according to the predicted adult height, but we do not yet know the accuracy of the adult height prediction, since these methods were based on the data from normal children. Both methods appear to overestimate final height at the cessation of LHRH analog. Nor do we know exactly how much the patients will grow after the cessation of LHRH analog. A better treatment regimen will be established after all these patients who are now being treated reach their adult height. Acknowledgement The authors are grateful to Sumitomo Pharmaceutical Company Ltd., and Takeda Chemical Ind. Ltd for contributing GH and LHRH analog. References 1. Takano K, Tanaka T, Saito T (1994) Psychosocial adjustment in a large cohort of adults with growth hormone deficiency treated with growth hormone in childhood: Summary of a questionnaire survey. Acta Paediatr (Suppl) 399: Tanaka T (1994) Pubertal development in growth hormone-treated children. Clin Pediatr Endocrinol 3 (Suppl 5): Tanaka T, Yoshizawa A, Tanae A, Hibi I, Shizume K (1990) Relationships between puberty and growth at adolescence in growth-hormone-deficient males: Effect of growth hormone and of associated gonadal suppression therapy. Horm Res 33 (Supp14): Hashimoto N, Tanaka T, Tanae A, Yokoya S, Hibi I (1992) Growth pattern and final height of non-en-
5 COMBINED GH AND LHRH ANALOG TREATMENT IN SHORT CHILDREN S17 docrine short stature. J Jpn Pediatr Soc 96: Tanaka T, Suwa S, Yokoya S, Hibi I, Watanabe T (1990) Prediction of final height at onset of puberty. J Jpn Pediatr Soc 94: Tanaka T, Satoh M, Ishikawa M, Tachibana K, Yokoya S, Yano K (1996) Analysis of natural growth of children with short stature at prepuberty or at final height II. Follow-up at hospitals. J Jpn Pediatr Soc (submitted). 7. Hibi I, Tanaka T, Tanae A, Kagawa J, Hashimoto N, Yoshizawa A, Shizume K (1989) The influence of gonadal function and the effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children. J Clin Endocrinol Metab 69: Murata M (1993) Japanese specific bone age standard on the TW2. Clin Pediatr Endocrinol 2 (Suppl 3):
Somatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationThe Usefulness of GnRH and hcg Testing for the Differential Diagnosis of Delayed Puberty and Hypogonadotropic Hypogonadism in Prepubertal Boys
The Usefulness of GnRH and hcg Testing for the Differential Diagnosis of Delayed Puberty and Hypogonadotropic Hypogonadism in Prepubertal Boys Naoko SATO 1), Noriyuki KATSUMATA 1), Reiko HORIKAWA 2) and
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe science behind igro
The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts
More informationPubertal Development in Japanese Boys
Clin Pediatr Endocrinol 1993; (SuPP13): 7-14 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Pubertal Development in Japanese Boys Kenji Fujieda, M.D., Ph. D. Department of Pediatrics,
More informationFinal Height in Patients with Turner Syndrome after
Clin Pediatr Endocrinol 1997; 6(Suppl 10), 51-57 Copyright (C) 1997 by The Japanese Society for Pediatric Endocrinology Final Height in Patients with Turner Syndrome after Treatment with GH Kazue Takano,
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationEndocrine: Precocious Puberty Health care guidelines for Spina Bifida
Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.
More informationGrowth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
Sotos and Tokar International Journal of Pediatric Endocrinology 2014, 2014:15 RESEARCH Open Access Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationZohreh Karamizadeh, MD; Anis Amirhakimi*, MD; Gholamhossein Amirhakimi, MD
Original Article Iran J Pediatr Jun 2014; Vol 24 (No 3), Pp: 293-299 Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly
More informationDose Effects of Growth Hormone during Puberty
Puberty Horm Res 2003;60(suppl 1):52 57 DOI: 10.1159/000071226 Dose Effects of Growth Hormone during Puberty Paul Saenger Department of Pediatrics, Division of Pediatric Endocrinology, Childrens Hospital
More informationPUBLICATIONS Abstracts and publications on the psychological data available.
Page 1 of 9 Synopsis TITLE OF TRIAL : The Effects of Biosynthetic Human Growth Hormone Treatment in the Management of Children with Familial Short Stature. Protocol B: A Comparative Evaluation of Growth
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationOriginal. Tsuyoshi Isojima 1), 2), 3), Tomonobu Hasegawa 1), 4), Susumu Yokoya 1), 5) 1), 6) and Toshiaki Tanaka
2017, 64 (9), 851-858 Original The response to growth hormone treatment in prepubertal children with growth hormone deficiency in Japan: Comparing three consecutive years of treatment data of The Foundation
More informationEffect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
Biomedical Research 2017; 28 (15): 6813-6817 ISSN 0970-938X www.biomedres.info Effect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
More informationHyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea
Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku
More informationKAZUE TAKANO, KAZUO SHIZUME, ITSURO HIBI and Members of Committee for the Treatment of Pituitary Dwarfism in Japan
Endocrinol. Japon. 1988, 35 (3), 477-484 A Comparison of Subcutaneous and Intramuscular Administration of Human Growth Hormone (hgh) and Increased Growth Rate by Daily Injection of hgh in GH Deficient
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationLong-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty
Clin Pediatr Endocrinol 1993; (Supp13):49-56 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Long-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty Paul A.
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationTwenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome
Twenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome MARIA CORAZON R. VILLADOLID, KAZUE TAKANO, NAOMI HIZUKA, KUMIKO ASAKAWA, IZUMI SUKEGAWA, REIKO HORIKAWA AND KAZUO SHIZUME
More informationCase Report Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor
Case Reports in Pediatrics Volume 2015, Article ID 738571, 4 pages http://dx.doi.org/10.1155/2015/738571 Case Report Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase
More informationPuberty and Pubertal Disorders Part 3: Delayed Puberty
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 3: Delayed Puberty These podcasts are designed to give medical students an overview
More informationDate: 24 April-2007 Trial ID: GHTUR/E/2 Version: 2 Integrated Clinical Trial Report Status: Final ICTR Synopsis Page: 1 of 5
ICTR Synopsis Page: 1 of 5 Synopsis TITLE OF TRIAL INDUCTION OF PUBERTY WITH 17 Β-ESTRADIOL IN GIRLS WITH TURNER SYNDROME. AN OPEN RANDOMISED TRIAL TRIAL CODE: GHTUR/E/2 INVESTIGATORS IN TOTAL, 35 PRINCIPAL
More informationTRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST
TRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST DISCLOSURE No potential conflict of interest OBJECTIVES Review timing considerations for
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationEndocrine Late Effects in Survivors of Pediatric SCT
Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationThe Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty
ORIGINAL ARTICLE The Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty Yi-Ching Tung, Jing-Sheng Lee, Wen-Yu Tsai, Pei-Hung Hsiao Background/Purpose:
More informationPhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationIntrauterine Growth Retardation or Small Gestational Age. Series N.14
Intrauterine Growth Retardation or Small Gestational Age Series N.14 Patient s Guide Average Readability Leaflet Intrauterine Growth Retardation- Series 14 (Revised August 2006) This leaflet was produced
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More information4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!
Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The
More informationClinical trials of GH treatment in patients with Turner s syndrome in Japan a consideration of final height
European Journal of Endocrinology (1997) 137 138 145 ISSN 0804-4643 Clinical trials of GH treatment in patients with Turner s syndrome in Japan a consideration of final height K Takano 1,6, M Ogawa 2,6,
More informationand Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects
Serum Follicular - Stimulating Hormone and Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects ROBERT PENNY, THOMAS P. FOLEY, JR., and ROBERT
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 2: Precocious Puberty. These podcasts are designed to give medical students an overview
More informationAdult height in constitutionally tall stature:
Archives ofdisease in Childhood 1992; 67: 1357-1362 1357 Department of Paediatrics, University of Berne, Berne, Switzerland E E Joss R Temperli P E Mullis Correspondence to: Professor E E Joss, Universitats-Kinderklinik,
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationGrowth and Puberty: A clinical approach. Dr Esko Wiltshire
Growth and Puberty: A clinical approach Dr Esko Wiltshire NOTHING TO DISCLOSE Why is this character short? Food Psychosocial factors Major Systems (+drugs) Genetic potential Perinatal Classical Hormones
More informationHHS Public Access Author manuscript Endocr Pract. Author manuscript; available in PMC 2017 March 09.
BIRD S-EYE VIEW OF GnRH ANALOG USE IN A PEDIATRIC ENDOCRINOLOGY REFERRAL CENTER Sara E. Watson, MD, MS 1, Ariana Greene, BS 1, Katherine Lewis, MD, MS 2, and Erica A. Eugster, MD 1 1 Section of Endocrinology
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationClinical Standards for GH Treatment in Childhood & Adolescence.
Clinical Standards for GH Treatment in Childhood & Adolescence. The Clinical Standards for GH treatment have been produced by the Clinical Committee of the BSPED. They are evidence based where possible
More informationRunning title: Growth hormone coverage for idiopathic short stature
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationPrecocious Puberty. Disclosures. No financial disclosures 2/28/2019
Precocious Puberty Bracha Goldsweig, MD Pediatric Endocrinologist Children s Hospital and Medical Center, Omaha, NE University of Nebraska Medical Center Disclosures No financial disclosures 1 Objectives
More informationCritical Growth Phases for Adult Shortness
American Journal of Epidemiology Copyright 2000 by The Johns Hopkins University chool of Hygiene and Public Health All rights reserved Vol. 2, o. 2 Printed in U..A. Critical Growth Phases for Adult hortness
More informationCorrelation of Serum Follicular Stimulating Hormone
Correlation of Serum Follicular Stimulating Hormone (FSH) and Luteinizing Hornone (LH) as Measured by Radioimmunoassay in Disorders of Sexual Development ROBERT PENNY, HARVEY J. GUYDA, ALIcE BAGHDASSARIAN,
More informationA single sample GnRHa stimulation test in the diagnosis of precocious puberty
Yazdani et al. International Journal of Pediatric Endocrinology 212, 212:23 RESEARCH Open Access A single sample GnRHa stimulation test in the diagnosis of precocious puberty Parvin Yazdani 1*, Yuezhen
More informationClinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
International Endocrinology Volume 2015, Article ID 247386, 7 pages http://dx.doi.org/10.1155/2015/247386 Clinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central
More informationKENJI OHYAMA, MASANORI OHTA, YosHIKo NAKAGOMI, YOSHIE SHIMURA, T0M0AKI SANG, KAZUMASA SATO, SHINPEI NAKAZAWA, AND HIROMICHI ISHIKAWA*
Endocrine Journal 1997, 44 (4), 459-465 Restoration of Seminiferous Tubular Function after Discontinuation of Long-Term Gonadotropin-Releasing Hormone Agonist Administration in Premature Male Rats KENJI
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationRole of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases
Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases Laura Stewart, M.D., F.R.C.P.(C), Paul Steinbok, M.B.B.S., F.R.C.S.(C), and Jorge Daaboul,
More informationPENS 2017 Minneapolis, MN April 27, Disclosure. Objectives: Growth Hormone Guidelines Roundtable
Growth Hormone Guidelines Roundtable PENS 2017 Minneapolis, MN April 27, 2017 Panelists: Mary S. Burr, DNP, CPNP-PC Catherine P. Metzinger, AAS, RN, CDE Bradley S. Miller, MD, PhD Disclosure Dr. Miller
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationGuidelines for the Clinical Care of Persons with Gender Dysphoria
Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,
More informationBone Development. V. Gilsanz and O. Ratib, Hand Bone Age, DOI / _2, Springer-Verlag Berlin Heidelberg 2012
Bone Development 2 Skeletal maturity is a measure of development incorporating the size, shape and degree of mineralization of bone to define its proximity to full maturity. The assessment of skeletal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Mecasermin (Increlex) Reference Number: CP.PHAR.150 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationand premature puberty associated with lymphoblastic leukaemia
Archives of Disease in Childhood, 1987, 62, 117-1112 Precocious treatment of acute and premature puberty associated with lymphoblastic leukaemia A D LEIPER,* R STANHOPE,t P KITCHING,* AND J M CHESSELLS*
More informationGuidelines for the Clinical Care of Persons with Gender Dysphoria
Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationGrowth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain
Lundberg et al. BMC Endocrine Disorders (2015) 15:84 DOI 10.1186/s12902-015-0080-8 RESEARCH ARTICLE Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Open Access Elena Lundberg
More informationLumbar spine and proximal femur BMD values in Turkish girls and the
Lumbar spine and proximal femur and the effect of precocious puberty on BMD. Ersoy Kekilli 1, Mustafa Arif Aluçlu 1, Fatih Batı 1, İsmail Köksal 1 1 Inonu University, Medical Faculty, Department of Nuclear
More informationGrowth Hormone: Review of the Evidence
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Growth Hormone: Review of the Evidence
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationPaul Hofman. Professor. Paediatrician Endocrinologist Liggins Institute, The University of Auckland, Starship Children Hospital, Auckland
Professor Paul Hofman Paediatrician Endocrinologist Liggins Institute, The University of Auckland, Starship Children Hospital, Auckland 9:25-9:50 Endocrine and Metabolic Consequences of Being Born Preterm
More informationAction of reproductive hormones through the life span 9/22/99
Action of reproductive hormones through the life span Do reproductive hormones affect the life span? One hypothesis about the rate of aging asserts that there is selective pressure for either high rate
More informationLarge height gain by growth hormone therapy in combination with GnRH analog in two pubertal sibs with a GH-releasing hormone receptor mutation
Large height gain by growth hormone therapy in combination with GnRH analog in two pubertal sibs with a GH-releasing hormone receptor mutation 3 Marie J.E. Walenkamp 1, Alberto M. Pereira 2, Wilma Oostdijk
More informationGrowth promoting treatment: When discretion is the better part of value
Growth promoting treatment: When discretion is the better part of value David B. Allen, MD Professor of Pediatrics University of Wisconsin School of Medicine and Public Health Head of Division of Diabetes
More informationGrowth and DMD Endocrine aspects of care
Growth and DMD Endocrine aspects of care Meilan Rutter, MB,BCh, FRACP Division of Endocrinology Cincinnati Children s Hospital Medical Center July 2007 Where are we now? Inactive Reactive Proactive CCHMC
More informationThis CNE activity is supported by an educational grant from Novo Nordisk Inc.
This CNE activity is supported by an educational grant from Novo Nordisk Inc. Objectives Differentiate between normal growth variants and growth variants that are linked to a disorder Describe the process
More informationWhy is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
More informationPREP Pediatric Endocrinology General session. Srinath Sanda, M.D. UC San Francisco
PREP 2017 Pediatric Endocrinology General session Srinath Sanda, M.D. UC San Francisco Disclosures o I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or
More informationGrowth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A
Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationGrowth and Development in Turner Syndrome
Growth and Development in Turner Syndrome Edna Roche Consultant Paediatric Endocrinologist, National Children s Hospital, AMNCH and the University of Dublin Trinity College Growth in Turner Syndrome Short
More informationJudith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction
Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEndocrine. Joe O Neil, MD, Chair
Endocrine Joe O Neil, MD, Chair Definitions Endocrine Section is comprised of 3 parts: Precocious Puberty Short Stature and Effect of Growth Hormone Obesity Puberty Definitions Puberty is defined as presence
More informationCommonKnowledge. Pacific University. Peter Bodmer Pacific University. Summer
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-8-2015 Human chorionic gonadotropin (hcg) for Improved Virility without Negative
More informationSeCondary Osteoporosis & its Therapy Duchenne Muscular Dystrophy SCOT-DMD
SeCondary Osteoporosis & its Therapy Duchenne Muscular Dystrophy SCOT-DMD Acknowledgement S Joseph J Dunne M DiMarco C Duncanson I Horrocks S Shepherd and students Research radiographers & MRI Physics
More informationGrowth after renal transplants
Archives of Disease in Childhood, 1983, 58, 110-114 Growth after renal transplants M BOSQUE, A MUNIAN, M BEWICK, G HAYCOCK, AND C CHANTLER Evelina Children's Department, Guy's Hospital, London SUMMARY
More informationThe somatopause. What stops our growth and diminishes GH secretion?
The somatopause What stops our growth and diminishes GH secretion? What extends or stops statural growth? Statural growth is extended if the early growth rate is slowed underfed adolescents grow for a
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationPaul Hofman. Professor. Paediatrician Endocrinologist Liggins Institute, The University of Auckland, Starship Children Hospital, Auckland
Professor Paul Hofman Paediatrician Endocrinologist Liggins Institute, The University of Auckland, Starship Children Hospital, Auckland 14:00-14:55 WS #108: Common pubertal variants how to distinguish
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next
More informationGrowth disorders in adolescents
FOCUS Growth disorders in adolescents Tashunka Taylor-Miller, Peter J Simm Background Growth is one of the fundamental processes of adolescent development. Careful history and examination, and relevant
More informationOBJECTIVES. Rebecca McEachern, MD. Puberty: Too early, Too Late or Just Right? Special Acknowledgements. Maryann Johnson M.Ed.
1 Puberty: Too early, Too Late or Just Right? Maryann Johnson M.Ed., BSN, RN Special Acknowledgements Rebecca McEachern, MD OBJECTIVES Illustrate basic endocrine system and hormonal pathways Define the
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationEndocrinological Outcome Among Treated Craniopharyngioma Patients
Endocrinological Outcome Among Treated Craniopharyngioma Patients Afaf Al Sagheir, MD Head & Consultant, Section of Endocrinology/Diabetes Department of Pediatrics KFSH&RC Introduction Craniopharyngiomas
More information2. Skeletal System. Aged Osteoporosis (post menopausal fractures - decreased bone density/ length) Loading Effects. Wednesday, 17 June 2015
BIOL1900 Page 1 2. Skeletal System Wednesday, 17 June 2015 11:32 am Bones Very Strong Not inert i.e. grow/ decrease in size Compression strength ~170MPa (Steel ~300Mpa, aluminium ~80MPa) Lower tensile
More informationX/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Prediction of Long-Term Response to Recombinant Human
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationAdult height of prepubertal short children born small for gestational age treated with GH
European Journal of Endocrinology (2005) 152 835 843 ISSN 0804-4643 CLINICAL STUDY Adult height of prepubertal short children born small for gestational age treated with GH Myriam Rosilio, Jean-Claude
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More information